Gemcitabine (1000 mg/m2)

DRUG9 trials

Conditions

Advanced Pancreatic CancerBiliary Tract Cancer (BTC)Diffuse Pleural Mesothelioma (DPM)Gastric CancerHead and Neck CancerHigh-grade B-cell LymphomaLarge B-Cell Lymphoma (LBCL)Melanoma

Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RecruitingNCT04198766

Inhibrx Biosciences, IncGastric Cancer, Head and Neck Cancer, Melanoma +5

Start: 2019-12-10End: 2033-07-01Target: 340Updated: 2026-07-29

Phase 2

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

TerminatedNCT00550004

SciClone PharmaceuticalsPancreatic Cancer

Start: 2007-09-30End: 2009-10-31Target: 153Updated: 2011-06-08

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

CompletedNCT07411144

National Cancer Institute, EgyptDiffuse Pleural Mesothelioma (DPM)

Start: 2020-03-15End: 2023-03-15Updated: 2026-02-13

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

RecruitingNCT07451652

Hospital Universitario Dr. Jose E. GonzalezRelapsed/Refractory Diffuse Large B Cell Lymphoma

Start: 2026-03-17End: 2027-09-01Target: 10Updated: 2026-04-01

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Not yet recruitingNCT07498907

Peking University First HospitalUpper Tract Urothelial Carcinoma

Start: 2026-05-01End: 2034-03-01Target: 192Updated: 2026-03-27

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Not yet recruitingNCT07578337

Nelum CorpAdvanced Pancreatic Cancer, Untreated

Start: 2026-07-15End: 2029-02-28Target: 40Updated: 2026-05-13

Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma

Not yet recruitingNCT07774234

The First Affiliated Hospital of Soochow UniversityHigh-grade B-cell Lymphoma, Large B-Cell Lymphoma (LBCL)

Start: 2026-08-20End: 2030-08-20Target: 39Updated: 2026-08-19

Phase 3

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Not yet recruitingNCT07272109

Fudan UniversityPancreatic Cancer

Start: 2026-01-01End: 2028-12-30Target: 210Updated: 2025-12-15

Phase 4

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Not yet recruitingNCT07619235

Xianglin YuanBiliary Tract Cancer (BTC)

Start: 2026-07-01End: 2028-12-31Target: 32Updated: 2026-06-01

BMC Cancer2026-03-26

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058

The Journal of Immunology2025-11-01

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Journal of Clinical Oncology2025-05-28

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Journal for ImmunoTherapy of Cancer2025-05-014 citations

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Regular and Young Investigator Award Abstracts2023-10-311 citations

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice

Regular and Young Investigator Award Abstracts2023-10-31

856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

Regular and Young Investigator Award Abstracts2021-11-019 citations

RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients.

2011-07-2271 citations